Business
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach Featured AACR Advances session underscores Nurix’s scientific leadership in targeted protein degradation and induced proximity pharmacology BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developin
About this update from Nurix Therapeutics, Inc.
[{"type":"image","alt":"Nurix Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Nurix Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":124,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IT._.OAst_JFnczbzmuHbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMA--/https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff","width":124,"height":59}},"lazy":false},{"type":"text","content":"Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs","length":99,"tagName":"p"},{"type":"text","content":"Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach","length":113,"tagName":"p"},{"type":"text","content":"Featured AACR Advances session underscores Nurix’s scientific leadership in targeted protein degradation and induced proximity pharmacology","length":139,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, today announced new preclinical data from multiple oncology programs at the American Association for Cancer Research (AACR) Annual Meeting 2026.","length":332,"tagName":"p"},{"type":"text","content":"The presentations highlight continued progress across Nurix’s oncology pipeline, including programs targeting pan-mutant BRAF, CBL-B and Aurora Kinase A (AURKA), as well as a featured AACR Advances session presentation highlighting the broader scientific progress and clinical translation of targeted protein degradation. Collectively, these data provide additional mechanistic validation of Nurix’s approach to CBL-B, Aurora kinase A (AURKA) and mutant BRAF to address key limitations of traditional approaches, including resistance, incomplete pathway suppression, and inability to target non-enzymatic protein functions.","length":623,"tagName":"p"},{"type":"text","content":"“These data, together with our participation in the AACR Advances session, highlight the growing clinical and scientific validation of targeted protein degradation as a new therapeutic modality,” said Arthur T. Sands, M.D., Ph.D., president and chief exec...